Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RATIONALISE: Stopping vs Continuing Ig in Hypogammaglobulinemia
NCT05678621Phase 3Recruiting
- Sponsor
- Monash University
- Start
- Nov 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trimethoprim + sulfamethoxazole in bacterial infectious disease (3 arms), sponsored by Monash University. Primary endpoint: Event-free survival at 12 months. Started Nov 2022; status: recruiting.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
bacterial infectious disease
Beyond the preview
Go deeper on NCT05678621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678621.